Insider Transactions in Q2 2022 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
1,341
-50.0%
|
$61,686
$46.79 P/Share
|
|
Jun 23
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
15,000
-4.99%
|
$675,000
$45.0 P/Share
|
|
Jun 22
2022
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-7.96%
|
$440,000
$44.51 P/Share
|
|
Jun 17
2022
|
Victoria L. Brown Program Team Lead |
SELL
Open market or private sale
|
Direct |
2,698
-9.75%
|
$121,410
$45.0 P/Share
|
|
Jun 17
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,005
+3.42%
|
$66,010
$2.67 P/Share
|
|
Jun 16
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
10,000
-25.48%
|
$410,000
$41.78 P/Share
|
|
Jun 16
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.3%
|
$130,000
$13.85 P/Share
|
|
Jun 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$48,750
$39.29 P/Share
|
|
Jun 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Jun 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.01%
|
$37,000
$2.67 P/Share
|
|
Jun 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.33%
|
$528,000
$44.09 P/Share
|
|
Jun 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.23%
|
$102,500
$41.78 P/Share
|
|
May 27
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-19.86%
|
$430,000
$43.0 P/Share
|
|
May 16
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$48,750
$39.18 P/Share
|
|
May 16
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
May 02
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.18%
|
$107,500
$43.56 P/Share
|
|
Apr 29
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-0.45%
|
$176,000
$44.43 P/Share
|
|
Apr 29
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.44%
|
$8,000
$2.67 P/Share
|
|
Apr 25
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
3,750
-3.63%
|
-
|
|
Apr 25
2022
|
Nur Nicholson Chief Technical Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-5.27%
|
-
|
|
Apr 25
2022
|
Karen Lewis Chief People Officer |
SELL
Other acquisition or disposition
|
Direct |
1,250
-5.33%
|
-
|
|
Apr 25
2022
|
Jeffrey Eisele Chief Development Officer |
SELL
Other acquisition or disposition
|
Direct |
1,250
-3.79%
|
-
|
|
Apr 25
2022
|
Cedric Francois Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
12,500
-1.31%
|
-
|
|
Apr 25
2022
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-3.83%
|
$250,000
$50.0 P/Share
|
|
Apr 22
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+18.0%
|
$280,000
$14.0 P/Share
|
|
Apr 21
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-4.26%
|
-
|
|
Apr 21
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-3.59%
|
-
|
|
Apr 21
2022
|
Federico Grossi Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-1.61%
|
-
|
|
Apr 21
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-0.21%
|
-
|
|
Apr 21
2022
|
David O. Watson General Counsel |
SELL
Other acquisition or disposition
|
Direct |
1,875
-1.42%
|
-
|
|
Apr 20
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
7,000
-19.73%
|
$364,000
$52.53 P/Share
|
|
Apr 20
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+16.48%
|
$105,000
$15.52 P/Share
|
|
Apr 14
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$62,500
$50.9 P/Share
|
|
Apr 14
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Apr 05
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
609
-1.15%
|
$36,540
$60.09 P/Share
|
|
Apr 05
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
609
+1.14%
|
$7,917
$13.85 P/Share
|
|
Apr 04
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,504
-2.14%
|
$196,224
$56.83 P/Share
|
|
Apr 04
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,504
+5.91%
|
$45,552
$13.85 P/Share
|
|
Apr 01
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
11,496
-18.04%
|
$632,280
$55.05 P/Share
|
|
Apr 01
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,496
+15.28%
|
$149,448
$13.85 P/Share
|